AffiliationMenzies School of Health Research, Casuarina, Australia.
MetadataShow full item record
JournalJournal of Infectious Diseases
AbstractThe 21st century saw a shift in the cholera burden from Asia to Africa. The risk factors for cholera outbreaks in Africa are incompletely understood, and the traditional emphasis on providing safe drinking water and improving sanitation and hygiene has proven remarkably insufficient to contain outbreaks. Current killed whole-cell oral cholera vaccines (OCVs) are safe and guarantee a high level of protection for several years. OCVs have been licensed for >20 years, but their potential for preventing and control cholera outbreaks in Africa has not been realized. Although each item in the long list of technical reasons why cholera vaccination campaigns have been deferred is plausible, we believe that the biggest barrier is that populations affected by cholera outbreaks are underprivileged and lack a strong political voice. The evaluation and use of OCVs as a tool for cholera control will require a new, more compassionate, less risk-averse generation of decision makers.
- Cost-effectiveness of oral cholera vaccine in a stable refugee population at risk for epidemic cholera and in a population with endemic cholera.
- Authors: Murray J, McFarland DA, Waldman RJ
- Issue date: 1998
- Costs of illness due to cholera, costs of immunization and cost-effectiveness of an oral cholera mass vaccination campaign in Zanzibar.
- Authors: Schaetti C, Weiss MG, Ali SM, Chaignat CL, Khatib AM, Reyburn R, Duintjer Tebbens RJ, Hutubessy R
- Issue date: 2012
- The case for reactive mass oral cholera vaccinations.
- Authors: Reyburn R, Deen JL, Grais RF, Bhattacharya SK, Sur D, Lopez AL, Jiddawi MS, Clemens JD, von Seidlein L
- Issue date: 2011 Jan 25
- Cholera in Africa: new momentum in fighting an old problem.
- Authors: Mengel MA
- Issue date: 2014 Jul
- When, how, and where can oral cholera vaccines be used to interrupt cholera outbreaks?
- Authors: Clemens J, Holmgren J
- Issue date: 2014